Lilly Research Laboratories (LRL) is responsible for the discovery, development, and clinical evaluation of pharmaceutical products and for providing ongoing scientific support for marketed products.
Discovering and developing innovative therapies for many of the world's unmet medical needs is at the core of LRL's mission.
Approximately 7,000 people work in LRL in the U.S. and other countries around the world. Research and development locations in the United States include several sites in Indiana and California.
The most recent listing of sites has been revised to United States, Canada, China, England, Japan, Singapore, Spain, and a joint venture facility in Australia. In addition, LRL conducts clinical research in more than 50 countries around the world.
Research Pipeline
Improving patient outcomes is the goal of all research at Lilly Research Laboratories. To achieve this goal, LRL has built one of the best mid-stage pipelines in the industry with approximately four dozen distinct compounds in clinical development, including 17 priority biotech and small-molecule candidates, all aimed at improving the lives of patients around the globe.
Discovering New Drugs
Lilly is among the industry's leaders in investing in research and development. The process of discovering, testing and developing a new drug is complex, costly, and time-consuming — costing $800 million or more and spanning 10 to 15 years. In recent years, we have taken steps to accelerate the development of our medicines so that they can reach patients faster.
Value of Medicine
Over the years, scientists have made many breakthrough discoveries in new medicines to help patients live longer and healthier lives. But these new medicines also help control health care costs and strengthen the economy. Learn more about how medicines improve health and enhance life.
Principles of Medical Research
Lilly has established policies, standards, and protections throughout the R&D process to ensure that patient needs are foremost at all times. This begins with our Principles of Medical Research, an overarching statement about how and why Lilly conducts research, its relationship to researchers, and how it shares research and development results. Learn More
ImClone Systems acquisition strengthens Lilly’s oncology pipeline and biotech capabilities.
Lilly has a rich history and deep expertise in oncology, which will be augmented by ImClone’s culture of discovery. ImClone’s pipeline adds several molecules in mid-to late-stage clinical development targeting virtually all major solid tumor types. These targeted therapies, three of which have the potential to be in Phase III in 2009, add to Lilly’s own oncology pipeline of 13 compounds in clinical development. Learn More
Partnerships
At Lilly, we value partnerships. Our history has proven — and our strategy continues to prove — that by working together, we can discover, develop, and deliver the innovative pharmaceutical therapies that will help people live longer, healthier, and more active lives. Learn More
